Inpharma Weekly

, Volume 1349, Issue 1, pp 11–12 | Cite as

IRIS: imatinib mesylate superior in first-line treatment of CML

Meeting report


Imatinib Chronic Myeloid Leukaemia Cytarabine Mesylate Imatinib Mesylate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2002

Personalised recommendations